SCHEMBL15946888

SCHEMBL15946888

COc1cc2ncnc(Nc3ccc(F)cc3)c2cc1C

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 17/20 0.83
KDR P35968 6/20 0.64
LCK P06239 6/20 0.64
RET P07949 3/20 0.63
FLT1 P17948 1/20 0.63
GAK O14976 1/20 0.63
RIPK2 O43353 1/20 0.63
STK10 O94804 1/20 0.63
FLT3 P36888 1/20 0.63
JAK3 P52333 1/20 0.63
AAK1 Q2M2I8 1/20 0.63
Q6ZSR9 Q6ZSR9 1/20 0.63
SLK Q9H2G2 1/20 0.63
IRAK4 Q9NWZ3 1/20 0.63
RPS6KA6 Q9UK32 1/20 0.63
ALK Q9UM73 1/20 0.63
CLK1 P49759 2/20 0.62
ABCG2 Q9UNQ0 1/20 0.62
RAF1 P04049 1/20 0.61
BRAF P15056 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5478005 0.91 EGFR (1.00) EGFRKDRLCKRETFLT1
Hydrochloric Acid SCHEMBL5471121 0.90 EGFR (1.00) EGFRKDRLCKRETFLT1
Hydrochloric Acid SCHEMBL29623261 0.90 EGFR (1.00) EGFRKDRLCKRETFLT1
SCHEMBL14964757 0.86 EGFR (0.81) EGFRKDRLCKRETFLT1
SCHEMBL8213640 0.84 EGFR (0.85) EGFRKDRCLK1AURKAERBB2
SCHEMBL21442463 0.83 EGFR (0.84) EGFRKDRLCKRETFLT1
SCHEMBL31067662 0.82 EGFR (0.82) EGFRKDRAURKAAURKB
SCHEMBL18862788 0.82 EGFR (0.60) EGFRKDRLCKRETFLT1
SCHEMBL10121520 0.82 EGFR (0.86) EGFRKDRLCKRETFLT1
SCHEMBL12779087 0.82 EGFR (0.82) EGFRKDRLCKRETFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181277-B2 Aminoquinazoline derivatives and their salts and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-11-10 US disclosed
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE ABL1, PRKDC, JAK2 EGFR 460/4885KDR 949/4885LCK 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.